Planning Capital Management Corp Lineage Cell Therapeutics, Inc. Transaction History
Planning Capital Management Corp
- $142 Billion
- Q2 2024
A detailed history of Planning Capital Management Corp transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Planning Capital Management Corp holds 1,100 shares of LCTX stock, worth $1,001. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,100
Previous 100
1000.0%
Holding current value
$1,001
Previous $148,000
641.89%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding LCTX
# of Institutions
122Shares Held
94.4MCall Options Held
31.3KPut Options Held
400-
Broadwood Capital Inc New York, NY41.7MShares$37.9 Million3.19% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$8.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.47MShares$7.71 Million0.0% of portfolio
-
Defender Capital, Llc.4.97MShares$4.53 Million1.77% of portfolio
-
Logos Global Management LP San Francisco, CA4.7MShares$4.28 Million0.44% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $154M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...